Genizon BioSciences Licenses Ingenuity Pathways Analysis 3.0
News Oct 27, 2005
Genizon BioSciences and Ingenuity have announced that they have entered into an agreement for the licensing of Ingenuity Pathways Analysis 3.0, significantly accelerating Genizon's genes-to-targets process.
Genizon will integrate the newest release of Ingenuity Pathways Analysis into its Target Express platform. Genizon conducts whole genome association studies on common diseases to identify the major genes involved in these diseases and their interactions, which provide the basis for comprehensive GeneMaps of the disease.
The Ingenuity Pathways Analysis application is being applied to Genizon's lead programs - Crohn's disease, psoriasis, asthma, baldness, and schizophrenia - to identify targets in the near term.
Dr. John Hooper, President and CEO of Genizon commented, “Licensing the Ingenuity Pathways Analysis application is another step in our continued efforts to add value to our discoveries by taking the disease genes that we identify downstream to causative biochemical pathways and drug targets. The Ingenuity solution has immediately provided additional discoveries of novel, genetically validated drug targets.”
Peter DiLaura, Vice President of Sales and Customer Support at Ingenuity Systems added, “We are very pleased to have Genizon join our rapidly growing list of pharmaceutical, biotechnology, academic and government customers throughout the world.”
“More and more organizations are finding the Ingenuity Pathways Analysis solution to be a necessary technology when attempting to rapidly understand the biological functions and pathways relevant to their experimental data.”
Ingenuity Pathways Analysis 3.0 is designed to enable life science researchers to model, analyze and understand complex biological systems, and enhancing the productivity of research and development.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.